Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis Licenses Evrogen's Fluorescent Proteins

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cellectis Bioresearch today announced a non-exclusive agreement giving it access to Evrogen's fluorescent proteins.

The deal allows Paris-based Cellectis to incorporate the proteins into its own products, expanding its portfolio of genome engineering tools.

Financial and other terms were not disclosed.

Based in Moscow, Evrogen develops technologies for molecular and cell biology.

In a statement, Luc Selig, sales and marketing director for Cellectis, said that the integration matrix, which allows researchers to express a gene of interest, is a "key component" of the company's kits. The deal with Evrogen extends the choice of promoters and tags in these matrices, and as a result Cellectis can offer its clients "a full range of methods to achieve single-phase developments, thus saving valuable time during experiments."

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.